GlassScriptPhysician profile
George Sousanieh
NPI 1033514625
$2,496.81
in general payments reported to CMS, 2019-2025
10 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,888 · 2022: $129 · 2023: $124 · 2024: $106 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.84 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,887.58 | 2020 | |
| Bard Peripheral Vascular, INC. | $201.77 | 2023-2025 | Covera |
| Amgen INC. | $136.79 | 2025 | Krystexxa |
| Medtronic, INC. | $128.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $41.52 | 2024 | Lokelma |
| Calliditas Therapeutics US INC. | $25.00 | 2024 | |
| Ardelyx, INC. | $19.83 | 2024 | Ibsrela |
| Becton, Dickinson and Company | $19.54 | 2024 | Covera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $17.39 | 2023 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sousanieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.